{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:55:27Z","timestamp":1791230127933,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,8,16]],"date-time":"2017-08-16T00:00:00Z","timestamp":1502841600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s12185-017-2311-4","type":"journal-article","created":{"date-parts":[[2017,8,16]],"date-time":"2017-08-16T10:25:23Z","timestamp":1502879123000},"page":"777-786","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures: a prospective, open-label, single-arm phase 3b study"],"prefix":"10.1007","volume":"106","author":[{"given":"Shigeki","family":"Kushimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Brainsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Harman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,16]]},"reference":[{"key":"2311_CR1","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/ijs.12452","volume":"10","author":"K Toyoda","year":"2015","unstructured":"Toyoda K, Arihiro S, Todo K, Yamagami H, Kimura K, Furui E, et al. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study. Int J Stroke. 2015;10:836\u201342.","journal-title":"Int J Stroke."},{"key":"2311_CR2","unstructured":"IMS data Global Prescription Audit; MAT (moving annual total) 2014\/15 to 2015\/16."},{"key":"2311_CR3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijcard.2008.06.029","volume":"137","author":"H Inoue","year":"2009","unstructured":"Inoue H, Fujiki A, Origasa H, Ogawa S, Okumura K, Kubota I, et al. Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. Int J Cardiol. 2009;137:102\u20137.","journal-title":"Int J Cardiol"},{"key":"2311_CR4","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","volume":"285","author":"AS Go","year":"2001","unstructured":"Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370\u20135.","journal-title":"JAMA"},{"key":"2311_CR5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.105.595140","volume":"114","author":"Y Miyasaka","year":"2006","unstructured":"Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119\u201325.","journal-title":"Circulation"},{"key":"2311_CR6","doi-asserted-by":"crossref","first-page":"257S","DOI":"10.1378\/chest.08-0674","volume":"133","author":"S Schulman","year":"2008","unstructured":"Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:257S\u201398S.","journal-title":"Chest."},{"key":"2311_CR7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(96)01109-9","volume":"348","author":"G Palareti","year":"1996","unstructured":"Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D\u2019Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348:423\u20138.","journal-title":"Lancet"},{"key":"2311_CR8","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.STR.31.4.817","volume":"31","author":"T Yamaguchi","year":"2000","unstructured":"Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke. 2000;31:817\u201321.","journal-title":"Stroke"},{"key":"2311_CR9","first-page":"850","volume":"33","author":"H Moriyasu","year":"1993","unstructured":"Moriyasu H, Yasaka M, Oita J, Yamaguchi T. Warfarin therapy for secondary prevention of cardioembolic stroke with nonvalvular atrial fibrillation\u2013a retrospective study. Rinsho Shinkeigaku. 1993;33:850\u20135.","journal-title":"Rinsho Shinkeigaku."},{"key":"2311_CR10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","volume":"50","author":"AY Shen","year":"2007","unstructured":"Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50:309\u201315.","journal-title":"J Am Coll Cardiol"},{"key":"2311_CR11","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00003495-200969060-00001","volume":"69","author":"K Toyoda","year":"2009","unstructured":"Toyoda K. Pharmacotherapy for the secondary prevention of stroke. Drugs. 2009;69:633\u201347.","journal-title":"Drugs."},{"key":"2311_CR12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1474-4422(09)70340-0","volume":"9","author":"CJ Asch van","year":"2010","unstructured":"van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9:167\u201376.","journal-title":"Lancet Neurol."},{"key":"2311_CR13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2141.2001.03070.x","volume":"115","author":"HG Watson","year":"2001","unstructured":"Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol. 2001;115:145\u20139.","journal-title":"Br J Haematol"},{"key":"2311_CR14","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","volume":"141","author":"W Ageno","year":"2012","unstructured":"Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e44S\u201388S.","journal-title":"Chest"},{"key":"2311_CR15","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","volume":"141","author":"A Holbrook","year":"2012","unstructured":"Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e152S\u201384S.","journal-title":"Chest"},{"key":"2311_CR16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13054-016-1265-x","volume":"20","author":"R Rossaint","year":"2016","unstructured":"Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care. 2016;20:100.","journal-title":"Crit Care."},{"key":"2311_CR17","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1253\/circj.CJ-66-0092","volume":"78","author":"JCS Joint Working Group","year":"2014","unstructured":"JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). Circ J. 2014;78:1997\u20132021.","journal-title":"Circ J."},{"key":"2311_CR18","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.jstrokecerebrovasdis.2011.05.005","volume":"20","author":"Y Shinohara","year":"2011","unstructured":"Shinohara Y, Yanagihara T, Abe K, Yoshimine T, Fujinaka T, Chuma T, et al. III. Intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2011;20:S74\u201399.","journal-title":"J Stroke Cerebrovasc Dis."},{"key":"2311_CR19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000321766","volume":"31","author":"T Kuwashiro","year":"2011","unstructured":"Kuwashiro T, Yasaka M, Itabashi R, Nakagaki H, Miyashita F, Naritomi H, et al. Effect of prothrombin complex concentrate on hematoma enlargement and clinical outcome in patients with anticoagulant-associated intracerebral hemorrhage. Cerebrovasc Dis. 2011;31:170\u20136.","journal-title":"Cerebrovasc Dis."},{"key":"2311_CR20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00277-002-0568-y","volume":"82","author":"M Yasaka","year":"2003","unstructured":"Yasaka M, Oomura M, Ikeno K, Naritomi H, Minematsu K. Effect of prothrombin complex concentrate on INR and blood coagulation system in emergency patients treated with warfarin overdose. Ann Hematol. 2003;82:121\u20133.","journal-title":"Ann Hematol"},{"key":"2311_CR21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.thromres.2004.09.002","volume":"115","author":"M Yasaka","year":"2005","unstructured":"Yasaka M, Sakata T, Naritomi H, Minematsu K. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res. 2005;115:455\u20139.","journal-title":"Thromb Res"},{"key":"2311_CR22","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(14)61685-8","volume":"385","author":"AH Goldstein","year":"2015","unstructured":"Goldstein AH, Refaai MA, Milling TJ, Lewis B, Goldberg-Alberts R, Hug BA, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015;385:2077\u201387.","journal-title":"Lancet"},{"key":"2311_CR23","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","volume":"128","author":"R Sarode","year":"2013","unstructured":"Sarode R, Milling TJ, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin k antagonists presenting with major bleeding: a randomized, plasma-controlled phase IIIb study. Circulation. 2013;128:1234\u201343.","journal-title":"Circulation."},{"key":"2311_CR24","unstructured":"CSL Behring. Kcentra\u00ae Highlights of Prescribing Information. http:\/\/labeling.cslbehring.com\/PI\/US\/Kcentra\/EN\/Kcentra-Prescribing-Information.pdf . Accessed 2 June 2014."},{"key":"2311_CR25","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692\u20134.","journal-title":"J Thromb Haemost"},{"key":"2311_CR26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2011.08753.x","volume":"154","author":"D Keeling","year":"2011","unstructured":"Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, et al. Guidelines on oral anticoagulation with warfarin\u2014fourth edition. Br J Haematol. 2011;154:311\u201324.","journal-title":"Br J Haematol."},{"key":"2311_CR27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.08.017","volume":"312","author":"K Maeda","year":"2012","unstructured":"Maeda K, Koga M, Okada Y, Kimura K, Yamagami H, Okuda S, et al. Nationwide survey of neuro-specialists\u2019 opinions on anticoagulant therapy after intracerebral hemorrhage in patients with atrial fibrillation. J Neurol Sci. 2012;312:82\u20135.","journal-title":"J Neurol Sci"},{"key":"2311_CR28","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0049-3848(99)00079-1","volume":"95","author":"M Kohler","year":"1999","unstructured":"Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res. 1999;95:S13\u20137.","journal-title":"Thromb Res"},{"key":"2311_CR29","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1160\/TH11-01-0052","volume":"106","author":"F Dentali","year":"2011","unstructured":"Dentali F, Marchesi C, Giorgi Pierfranceschi M, Crowther M, Garcia D, Hylek E, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost. 2011;106:429\u201338.","journal-title":"Thromb Haemost."},{"key":"2311_CR30","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1001\/archinternmed.2012.4261","volume":"172","author":"DM Witt","year":"2012","unstructured":"Witt DM, Delate T, Garcia DA, Clark NP, Hylek EM, Ageno W, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med. 2012;172:1484\u201391.","journal-title":"Arch Intern Med"},{"issue":"96\u2013105","key":"2311_CR31","first-page":"e5","volume":"67","author":"TJ Milling Jr","year":"2016","unstructured":"Milling TJ Jr, Refaai MA, Goldstein JN, Schneider A, Omert L, Harman A, et al. Thromboembolic events after vitamin K antagonist reversal with 4-factor prothrombin complex concentrate: exploratory analyses of two randomized, plasma-controlled studies. Ann Emerg Med. 2016;67(96\u2013105):e5.","journal-title":"Ann Emerg Med"},{"key":"2311_CR32","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/acem.12911","volume":"23","author":"TJ Milling Jr","year":"2016","unstructured":"Milling TJ Jr, Refaai MA, Sarode R, Lewis B, Mangione A, Durn BL, et al. Safety of a four-factor prothrombin complex concentrate versus plasma for vitamin K antagonist reversal: an integrated analysis of two phase IIIb clinical trials. Acad Emerg Med. 2016;23:466\u201375.","journal-title":"Acad Emerg Med"},{"key":"2311_CR33","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/bja\/aes501","volume":"110","author":"AA Hanke","year":"2013","unstructured":"Hanke AA, Joch C, Gorlinger K. Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P\/N): a pharmacovigilance study. Br J Anaesth. 2013;110:764\u201372.","journal-title":"Br J Anaesth"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-017-2311-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2311-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2311-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T12:59:26Z","timestamp":1570021166000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-017-2311-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,16]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2311"],"URL":"https:\/\/doi.org\/10.1007\/s12185-017-2311-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,16]]}}}